LOS ANGELES, CA, April 26, 2019 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of non-invasive Electroceutical™ therapeutic devices, today announced a corporate update and business plan for the remainder of 2019.

Revenue projections for the first quarter ended March 31, 2019 are expected to increase by roughly 80% over the same quarter last year. Revenue for the quarter will exceed $40,000, as compared to $22,173 during the same period in the prior year.

Alan Collier, Endonovo’s Chief Executive Officer, stated “I am pleased to announce Endonovo continues to execute our business plan and strategy implemented after acquiring the PEMF assets and technology. During the first quarter of 2019, we have grown our sales network of numerous independent sales reps and distributors throughout the United States. These efforts have contributed to the increased revenues realized during the first quarter and anticipate only further growing in the future. We look forward to issuing the first quarter financial and operating results which will provide greater details very soon.”

“The opioid epidemic is one of the foremost issues in society today, all of which allows SofPulse to provide an alternative in post-operative pain management,” continued Mr. Collier. “In addition to the partnerships and getting into a second hospital, the first quarter has been productive to us from better understanding our market, initiating new business opportunities and expanding our workforce. The sales numbers and business accomplishments throughout the first quarter are a direct reflection of our partners and, as such, we are expanding our human capital in anticipation of what we believe will result in a vastly successful national roll-out.”

About Endonovo Therapeutics

Endonovo Therapeutics, Inc. is a commercial-stage developer of non-invasive wearable Electroceuticals™ therapeutic devices. The Company's current portfolio of commercial and clinical-stage wearable Electroceuticals™ therapeutic devices addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and Central Nervous System (CNS) Disorders, including traumatic brain injury (TBI), acute concussions, post-concussion syndrome and multiple sclerosis. The Company's non-invasive Electroceutical™ therapeutic device, SofPulse®, using pulsed short-wave radiofrequency at 27.12 MHz has been FDA-Cleared and CE Marked for the palliative treatment of soft tissue injuries and post-operative pain and edema, and has CMS National Coverage for the treatment of chronic wounds. The Company's current portfolio of pre-clinical stage Electroceuticals™ therapeutic devices address chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD), and ischemic stroke. The Company's non-invasive, wearable Electroceuticals™ therapeutic devices work by restoring key electrochemical processes that initiate anti-inflammatory and growth factor cascades necessary for healing to occur. www.endonovo.com

Safe Harbor Statement

This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release including words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company's estimates as of the date of the press release, and subsequent events and developments may cause the Company's estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates of its future financial performance as of any date subsequent to the date of this press release.

Investor Relations Contact: 

Endonovo Therapeutics, Inc. 
Mr. Andrew Barwicki
516-662-9461
Andrew@barwicki.com

www.endonovo.com